{"organizations": [], "uuid": "546ebc54ce670032c10a1cf53f68b6865f4c331a", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180208.html", "section_title": "Archive News &amp; Video for Thursday, 08 Feb 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-glaxosmithkline-says-viiv-healthca/brief-glaxosmithkline-says-viiv-healthcare-launches-new-two-drug-hiv-study-idUSFWN1PY0ND", "country": "US", "domain_rank": 408, "title": "BRIEF-GlaxoSmithKline Says ‍ViiV Healthcare Launches New Two-Drug HIV Study", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 1.0, "site_type": "news", "published": "2018-02-08T17:36:00.000+02:00", "replies_count": 0, "uuid": "546ebc54ce670032c10a1cf53f68b6865f4c331a"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-glaxosmithkline-says-viiv-healthca/brief-glaxosmithkline-says-viiv-healthcare-launches-new-two-drug-hiv-study-idUSFWN1PY0ND", "ord_in_thread": 0, "title": "BRIEF-GlaxoSmithKline Says ‍ViiV Healthcare Launches New Two-Drug HIV Study", "locations": [], "entities": {"persons": [], "locations": [{"name": "europe", "sentiment": "none"}, {"name": "australia", "sentiment": "none"}, {"name": "north america", "sentiment": "none"}], "organizations": [{"name": "glaxosmithkline plc", "sentiment": "negative"}, {"name": "reuters", "sentiment": "negative"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "Feb 8 (Reuters) - Glaxosmithkline Plc:\n* ‍VIIV HEALTHCARE LAUNCHES EIGHTH PHASE III STUDY IN TWO-DRUG REGIMEN PROGRAMME FOR HIV-1 TREATMENT​\n* ‍TANGO WILL SEEK TO ENROL APPROXIMATELY 550 ADULTS WITH HIV-1, FROM CLINICAL TRIAL SITES IN NORTH AMERICA, EUROPE, AUSTRALIA, AND JAPAN​\n* EXPECTS ‍RESULTS OF TANGO IN 2019 * STUDY TO INVESTIGATE DOLUTEGRAVIR AND LAMIVUDINE IN PATIENTS WITH HIV WHO HAVE ACHIEVED VIRAL SUPPRESSION ON TENOFOVIR ALAFENAMIDE FUMARATE-BASED REGIMEN​ Source text for Eikon: Further company coverage:\n ", "external_links": ["http://thomsonreuters.com/en/about-us/trust-principles.html"], "published": "2018-02-08T17:36:00.000+02:00", "crawled": "2018-02-09T17:00:44.007+02:00", "highlightTitle": ""}